In this study, we identified a hitherto unrecognized strong complement activation in treatment-naive classic male FD patients with missense or nonsense mutations as evidenced by high serum levels of the anaphylatoxins C3a and C5a, the small cleavage products of C3 and C5. The gene discussed is C5AR1; the disease is Fabry disease.